A Phase II Evaluation of Docetaxel (NSC628503) Plus Trabectedin (Yondelis; R279741, IND Pending) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Docetaxel (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Pegfilgrastim (Primary) ; Trabectedin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jul 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned End Date (1 Jul 2014) added as reported by ClinicalTrials.gov.
- 09 Jun 2010 Data from this study will be reported at the annual meeting of the American Society of Clinical Oncology (ASCO 2010), according to a PharmaMar media release.